Radiogenomics in the Era of Advanced Radiotherapy

M. R.S. Brothwell, C. M. West, A. M. Dunning, N. G. Burnet, G. C. Barnett*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Most radiogenomics studies investigate how genetic variation can help to explain the differences in early and late radiotherapy toxicity between individuals. The field of radiogenomics in photon beam therapy has grown rapidly in recent years, carving out a unique translational discipline, which has progressed from candidate gene studies to larger scale genome-wide association studies, meta-analyses and now prospective validation studies. Genotyping is increasingly sophisticated and affordable, and whole-genome sequencing may soon become readily available as a diagnostic tool in the clinic. The ultimate aim of radiogenomics research is to tailor treatment to the individual with a test based on a combination of treatment, clinical and genetic factors. This personalisation would allow the greatest tumour control while minimising acute and long-term toxicity. Here we discuss the evolution of the field of radiogenomics with reference to the most recent developments and challenges.

Original languageEnglish
Pages (from-to)319-325
Number of pages7
JournalClinical Oncology
Volume31
Issue number5
Early online date23 Mar 2019
DOIs
Publication statusPublished - 1 May 2019

Keywords

  • Genome-wide association studies
  • radiogenomics
  • radiotherapy toxicity

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'Radiogenomics in the Era of Advanced Radiotherapy'. Together they form a unique fingerprint.

Cite this